The latest prices for a box of different versions of Fezonastat announced

Fizonatan is a new oral selective neurokinin-3 (NK3) receptor antagonist developed by Astellas Pharma Inc. of Japan. The price difference between different versions significantly affects patients' medication choices. This article will provide patients with a comprehensive economic reference for medication by analyzing global market prices, domestic listing status, and medical insurance reimbursement policies.

The latest prices for a box of different versions of Fezonastat

The global market prices are obviously stratified, and the price differences between original drugs and generic drugs are significant. Understanding this price information can help patients make reasonable medication decisions.

The price of the original drug

The price of Fezonastat developed by Japan's Astellas Pharmaceutical Company is temporarily unclear, and it is usually relatively expensive.

Prices of mainstream generic drugs

The generic version of Fezonastat produced by Lucius Edition in Laos has a specification of 45mg*30 tablets/box and a price of approximately US$108.

Factors affecting price

The price of original drugs includes research and development costs and patent fees. Generic drugs have obvious price advantages because their production processes are mature and they are mostly produced in areas with low labor costs. Transportation costs and tariffs will also affect the final selling price.

Patients should verify the source of drugs when purchasing, purchase through formal channels and retain complete purchase receipts.

The domestic marketing situation of filazonatant

The admission process of filazonatant in mainland China is relatively slow, which directly affects the accessibility of the drug to domestic patients.

Approval status

As of now, Fezonatant has not been approved for marketing by the China National Medical Products Administration, and domestic patients are temporarily unable to obtain it through formal channels.

Clinical Use Status

A small number of medical institutions carry out clinical research use of drugs through special approval procedures, and most patients need to obtain drugs through cross-border medical treatment or overseas drug purchase.

Domestic patients should pay attention to the progress of drug approval and choose appropriate treatment options under the guidance of professional doctors.

The medical insurance reimbursement situation of nonazonatant

There are large differences in the medical insurance coverage of nonazonatant around the world, which directly affects the actual medication burden of patients.

Reimbursement policies in European and American countries

U.S. commercial insurance usually covers 60%-80% of drug costs, and the British NHS system includes fezonatant in the reimbursement list. The reimbursement ratio of German statutory medical insurance is about 75%.

Reimbursement status in Asia

After reimbursement by Japan’s medical insurance, the patient’s out-of-pocket ratio is about 30%. Singapore has reduced the patient burden through a special subsidy plan.

Self-pay patient choice

Patients who cannot enjoy medical insurance reimbursement can choose generic drugs. Some charities provide medication assistance programs to help patients with financial difficulties obtain treatment.

Understanding local medical insurance policies is crucial to reducing treatment costs. Patients can consult the local medical insurance department for the latest reimbursement details.